Advanced Hormone Sensitive Prostate Cancer Clinical Trial
| Verified date | November 2017 |
| Source | Ferring Pharmaceuticals |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.
| Status | Completed |
| Enrollment | 112 |
| Est. completion date | October 4, 2017 |
| Est. primary completion date | October 4, 2017 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer Exclusion Criteria: - Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded - Planned intermittent or short-term (< 12 months) degarelix treatment - Planned addition of, or switch to another form of androgen deprivation therapy during the study |
| Country | Name | City | State |
|---|---|---|---|
| Netherlands | Groene Hart Ziekenhuis (there may be other sites in this country) | Gouda |
| Lead Sponsor | Collaborator |
|---|---|
| Ferring Pharmaceuticals |
Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice | Up to 1 year |